Published: Friday, September 27th, 2013
Chair blog: shaping the future
Working to find new and effective ways to improve the lives of our patients and help shape the future of modern medicine is a key part of what we do here at the Golden Jubilee. Thanks to the hard work and dedication of our Cardiology Research Team, last month we made headlines around the world for doing just that.
Over the last five years, we have played a major role in the groundbreaking ‘PRAMI trial’ with two of our cardiologists, ProfessorKeith Oldroyd(senior author) and ProfessorColin Berry(co-author), making significant contributions to the research on the potential benefits of preventative angioplasty.
At the moment, if a patient suffers a serious heart attack they are admitted for an emergency angioplasty; this involves placing a thin mesh tube, known as a stent, into the blocked artery allowing blood to resume flowing normally.
In approximately half of these cases, the individual will have significant narrowing in other arteries, which could cause future complications; however it has been maintained that operating on more than one artery at a time is too dangerous.
What we have helped prove with the PRAMI trial however, is that thanks to recent advances in technology, operating on multiple arteries at the same time is not only possible, but reduces the risk of future heart attacks or death by 64%. In fact, these findings were so overwhelming that the trial could be relied upon and published in the New England Journal of Medicine ahead of schedule.
Although this is just one example of the many research trials currently taking place at the Golden Jubilee, it only takes one successful study to change the lives of so many people. I am personally very proud of all of our research contributions and the positive impact they may have for generations to come.
As with all new research, there are questions which still need to be answered before the PRAMI study can be become standard practice across the world. However, with such positive results behind us, we are set to play a key role in the next stage of this research and all with potentially significant benefits to patients if a new and robust approach system can be put in place.